ERBB2 and gastric cancer: Based on this clinical observation and the experimental evidences that some HER2-overexpressing breast cancer cell lines are sensitive to gefitinib, we speculated that HER2-overexpressing gastric cancer liver metastases were susceptible to gefitinib.